Medication Review in Women With Depression and Anxiety
Depression, Anxiety, Adherence, Patient
About this trial
This is an interventional treatment trial for Depression, Anxiety focused on measuring Medication management review service, Pharmaceutical care, Clinical pharmacist
Eligibility Criteria
Inclusion Criteria:
- Jordanian females or residents in Jordan for the last 12 months and planning to stay in Jordan for 6 months (the study follow-up period),
- above the age of 18 years
- diagnosed with depression and/or anxiety for at least 4 weeks duration
- taking medications for depression and/or anxiety
Exclusion Criteria:
- presence of a cognitive problem or sensory impairment which may prevent communication with the patient (reported by the patient's psychiatrist)
- being not able to speak or write Arabic (reported by the patient)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Intervention
Control
All pharmacist level counseling and education regarding treatment, adherence and self-care activities were delivered to the active group patients only (planned to take 15 minutes). Patient level TRPs (any TRP that could be resolved via patient education and counseling) were resolved directly with the patient by the clinical pharmacist. A letter with the identified TRPs (prioritized from most important to least important) for each patient in the active group was sent to the patient's psychiatrist by the researcher in sealed envelopes. The psychiatrist either accepted or rejected the recommendations. In case the recommendations were accepted, the psychiatrist implemented the recommended changes. Patients were informed by a phone call by the pharmacist to visit their psychiatrist soon after the recommendations were approved for the changes to be applied. If the recommendations were rejected, the psychiatrist stated the reason of rejection and discussed it with the pharmacist.
Control group patients also underwent the baseline interview with the researcher at the psychiatric clinic, TRPs were identified and documented. No intervention was provided by the pharmacist and no letter was sent to the patients' psychiatrists. In case a patient was found to have a life-threatening TRP, the patient was excluded from the study and reported to the psychiatrist due to ethical considerations. After study completion, all patients in the control group received the MMR service, and a letter with their TRPs and recommendations to resolve them was sent by the pharmacist to their psychologist